Civitas Therapeutics has obtained $20 million in Series A financing for development of its lead product, a DPI intended for the treatment of Parkinson's disease. The assets Civitas has licensed from Alkermes include a pipeline, delivery technology, and a manufacturing facility. Management of the new company includes Glenn Batchelder, CEO; Richard Batycky, Chief … [Read more...] about Alkermes pulmonary delivery spin-out Civitas gets $20 million
Business
Ritedose recalls albuterol inhalation solution vials in US
Contract manufacturer Ritedose has voluntarily recalled unit dose vials of albuterol inhalation solution due to mislabeling. The single dose vials contain a 2.5 mg/3 mL solution but are labeled as 0.5 mg/3 mL. The product was distributed across the United States and in Puerto Rico. Read the company's press release. … [Read more...] about Ritedose recalls albuterol inhalation solution vials in US
Intranasal insulin company CPEX acquired
A subsidiary of Footstar has entered into an agreement to acquire New Hampshire specialty pharma company CPEX, which is developing Nasulin intranasal insulin spray. Nasulin is in Phase 2 development, and CPEX has been seeking to license the product or to sell the program outright. Read the company's press release. … [Read more...] about Intranasal insulin company CPEX acquired
Procept and Ingeniatrics to team up on new spray dryer system
Belgian pharma equipment manufacturer Procept and Spanish tech company Ingeniatrics Tecnologías have signed an agreement to develop a new spray drying system based on Ingeniatrics' Flow Focusing technology, which is a "microfluidic technology capable of monodispersed droplet formation and manipulation, based on the production of capillary microjets that are … [Read more...] about Procept and Ingeniatrics to team up on new spray dryer system
Forest regains European rights to Colobreathe
Forest Laboratories has reached an agreement with Gruenenthal to reacquire the European rights to the Colobreathe colistin DPI for the treatment of P. aeruginosa infections in cystic fibrosis patients.The EMA is currently reviewing Forest's marketing application for the product. Read the company's press release. … [Read more...] about Forest regains European rights to Colobreathe
Generex gets another Canadian patent for aerosol formulations
Generex has received a patent from the Canadian Intellectual Property Office for its aerosol drug delivery platform, its 162nd patent for the technology. Although the company announcement emphasizes its buccal delivery platform, the patent is titled Aerosol Formulations for Buccal and Pulmonary Application. Generex's Oral-lyn buccal insulin spray is delivered via … [Read more...] about Generex gets another Canadian patent for aerosol formulations
Cypress Bioscience to merge with Ramius and Royalty Pharma
The board of Cypress Bioscience has agreed to be acquired by investment companies Ramius and Royalty Pharma for $6.50 per share, a total value of more than $250 million. In August 2010, Cypress acquired two OINDPs: Staccato nicotine for smoking cessation from Alexza and intranasal carbetocin for the treatment of autism symptoms from Marina Biotech (formerly Nastech). … [Read more...] about Cypress Bioscience to merge with Ramius and Royalty Pharma
Aptuit closing two facilities in Scotland
CRO Aptuit is planning to close two facilities where it conducts early stage development work on inhalation products. According to a spokesperson, all work currently in progress at the Livingston and Riccarton sites, both in Edinburgh, Scotland, will be completed, and other Aptuit sites will continue to provide similar services. Reportedly, the closures could cost up … [Read more...] about Aptuit closing two facilities in Scotland
Pulmatrix gets $5.7 million grant, hires new CBO
The Defense Advanced Research Projects Agency (DARPA) has awarded a $5.7 million grant to Pulmatrix for development of inhaled cationic airway lining modulator (iCALM) products to protect military personnel and civilians against airborne diseases. Read the press release on the grant. Pulmatrix also announced the hire of Eva Jack, formerly of MedImmune, as its new … [Read more...] about Pulmatrix gets $5.7 million grant, hires new CBO
Luitpold acquires Roxro and its Sprix nasal spray
Daiichi Sankyo subsidiary Luitpold Pharmaceuticals has acquired Roxro Pharma, which specializes in intranasal delivery of analgesics. Roxro's lead product is Sprix ketorolac tromethamine nasal spray for short-term pain management. Sprix received FDA approval in May 2010 but has not yet been marketed. Read the company's press release. … [Read more...] about Luitpold acquires Roxro and its Sprix nasal spray